

BIODELIVERY SCIENCES INTERNATIONAL INC  
Form 8-K  
July 16, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 16, 2015**

**BioDelivery Sciences International, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-31361**  
**(Commission**  
  
**File Number)**

**35-2089858**  
**(IRS Employer**  
  
**Identification No.)**

**4131 ParkLake Ave, Suite #225**

**Raleigh, NC**  
**(Address of principal executive offices)**

**27612**  
**(Zip Code)**

**Registrant's telephone number, including area code: 919-582-9050**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On July 16, 2015, BioDelivery Sciences International, Inc. (the Company) held its 2015 annual meeting of stockholders (the Annual Meeting). The number of shares of common stock entitled to vote at the Annual Meeting was 52,403,027. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 43,260,001. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and the director nominees were elected.

The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

Proposal 1: To elect Frank E. O'Donnell, Barry I. Feinberg and Samuel P. Sears, Jr. as Class I directors, each to serve for a three-year term that expires at the 2018 annual meeting of stockholders or until his successor is elected and qualified or until his earlier resignation or removal.

Nominee	Shares Voted For	Shares Abstaining	Broker Non-Votes
Frank E. O'Donnell, Jr.	29,893,735	1,472,783	11,893,483
Barry I. Feinberg	31,117,134	249,384	11,893,483
Samuel P. Sears, Jr.	30,961,670	404,848	11,893,483

Proposal 2: To ratify the appointment by the Audit Committee of the Company's Board of Directors of Cherry Bekaert LLP as the Company's registered public accounting firm for the fiscal year ending December 31, 2015.

Shares Voted For	Shares Against	Shares Abstaining	Broker Non-Votes
43,046,070	145,548	68,383	

Proposal 3: To approve an amendment to the Company's 2011 Equity Incentive Plan to, among other matters described in the Company's proxy statement on Schedule 14A for its 2015 Annual Meeting, as filed with the Securities and Exchange Commission on June 5, 2015 (the Proxy), increase the number of shares of common stock authorized for issuance under the plan by 2,250,000 shares from 8,800,000 to 11,050,000 (the Plan Amendment). A summary of the Plan Amendment was included as part of Proposal No. 3 contained on pages 41-50 of the Proxy. The information regarding the Plan Amendment contained herein is qualified in its entirety by reference to the actual terms of the Plan Amendment, which is filed as Annex A to the Proxy and incorporated herein by reference.

Shares Voted For	Shares Against	Shares Abstaining	Broker Non-Votes
29,433,979	1,906,434	26,105	11,893,483

### **Cautionary Note Regarding Forward-Looking Statements**

This Current Report on Form 8-K of the Company may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties, many of which are beyond the Company's control. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as projects, may, could, would, should, believes, expects, anticipates, estimates, intends, plans, or similar expressions. These statements are based upon current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

July 16, 2015

BIODELIVERY SCIENCES INTERNATIONAL, INC.

By: /s/ Ernest R. De Paolantonio

Name: Ernest R. De Paolantonio

Title: Chief Financial Officer, Secretary and Treasurer